Announced Date: 2025-05-19 (May 19, 2025), 2025-07-24 updated
Asset Name: SSGJ-707
Licensor: 3SBio, Inc (01530.HK) (Headquarter Shanghai City, China)
Licensee (Buyer): Pfizer Inc
Asset Target: Bispecific antibody targeting PD-1 and VEGF
Asset Modality: BsAbs
Current Stage: China phase 2 ;
Scope of Authority:
2025-05-19, exclusive global license to develop, manufacture and commercialize SSGJ-707 worldwide, excluding China. The option of commercialization rights in China.
2025-07-24, add exclusive rights in China.
Deal Detail:
Upfront payment of $1.25 billion, (add 150 million)
Milestone payments up to $4.8 billion
Royalties on net sales, tiered double-digit
Total 6.1 billion plus
Pfizer will also make a $100 million equity investment in 3SBio.
Link:
Pfizer Completes Licensing Agreement with 3SBio
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
